Mark Straley, Jan Egberts
Agendia has appointed Mark Straley its CEO, succeeding Jan Egberts, who has served as the interim CEO since October 2014.
Straley has more than 25 years of experience in developing and commercializing clinical diagnostics and laboratory services and most recently was president, anatomical pathology at Thermo Fisher Scientific. Prior to that, he was president and CEO of Metamark Genetics. Between 2005 and 2010, Straley was worldwide vice president of marketing, and then the worldwide president of Johnson & Johnson's Ortho Clinical Diagnostics.
Michael Lauer has been appointed deputy director for extramural research at the National Institutes of Health. From 2009 to the present, he has been the director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute. Lauer joined the NIH in 2007 as director of the Division of Prevention and Population Science at the NHLBI.
He received his M.D. from Albany Medical College in 1985. From 1993 to 2007, Lauer held leadership positions at the Cleveland Clinic, including as a professor of medicine, epidemiology, and biostatistics at the clinic's Lerner College of Medicine of Case Western Reserve University.
Myriad Genetics announced that Jan Schlüchter will be its new chief commercial officer starting Oct. 15. Schlüchter will lead operations in Europe and guide commercialization efforts around Myriad's tests. In his new role, Schlüchter will report to Gary King, Myriad's executive VP of international operations.
Schlüchter previously held various senior posts at Novartis and most recently was global head of key account management at the firm's headquarters in Basel, Switzerland. Before joining Novartis, Schlüchter was a consultant at McKinsey.
William Roper, Viktoria Brough
Human Longevity appointed William Roper its CFO. He had been the firm's interim CFO. The company also promoted Viktoria Brough to vice president of finance, controller.
Roper spent 17 years as executive vice president of SAIC and was the president and CEO of Verisign. Brough joined Human Longevity in 2014 after spending more than a decade as an auditor at Ernst & Young Assurance practice in San Diego.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.